KCM
MREO

Knoll Capital Management’s Mereo BioPharma MREO Stock Holding History

Knoll Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-260,470
Closed -$537K – 36
2025
Q3 		$537K Hold
260,470
– – 0.29% 33
2025
Q2 		$706K Hold
260,470
– – 0.5% 29
2025
Q1 		$586K Hold
260,470
– – 0.38% 30
2024
Q4 		$912K Hold
260,470
– – 0.59% 26
2024
Q3 		$1.07M Hold
260,470
– – 0.5% 26
2024
Q2 		$938K Hold
260,470
– – 0.63% 28
2024
Q1 		$860K Buy
260,470
+100,000
+62% +$339K 0.53% 30
2023
Q4 		$370K Buy
+160,470
New +$307K 0.31% 30

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Knoll Capital Management's MREO Position: Q4 2025 in Review

Knoll Capital Management sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 260,470 shares — an estimated $537K sold.

Knoll Capital Management first reported a position in MREO in Q4 2023 and held it in 8 quarters. The position peaked at $1.07M in Q3 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Knoll Capital Management reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Knoll Capital Management sold 260,470 Mereo BioPharma shares in Q4 2025, an estimated $537K.
  • Knoll Capital Management first reported a position in Mereo BioPharma in Q4 2023 and held it in 8 quarters.
  • Knoll Capital Management's Mereo BioPharma position peaked at $1.07M in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Knoll Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.